NANOBIOTIX SA - ADR (NBTX) Fundamental Analysis & Valuation

NASDAQ:NBTX • US63009J1079

Current stock price

30.54 USD
+1.51 (+5.2%)
Last:

This NBTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NBTX Profitability Analysis

1.1 Basic Checks

  • In the past year NBTX has reported negative net income.
  • NBTX had a negative operating cash flow in the past year.
  • In the past 5 years NBTX always reported negative net income.
  • In the past 5 years NBTX always reported negative operating cash flow.
NBTX Yearly Net Income VS EBIT VS OCF VS FCFNBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • NBTX has a worse Return On Assets (-114.32%) than 79.58% of its industry peers.
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBTX Yearly ROA, ROE, ROICNBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

  • NBTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBTX Yearly Profit, Operating, Gross MarginsNBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. NBTX Health Analysis

2.1 Basic Checks

  • NBTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NBTX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NBTX has been increased compared to 5 years ago.
  • NBTX has a worse debt/assets ratio than last year.
NBTX Yearly Shares OutstandingNBTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NBTX Yearly Total Debt VS Total AssetsNBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -11.18, we must say that NBTX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -11.18, NBTX is not doing good in the industry: 74.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.18
ROIC/WACCN/A
WACC7.82%
NBTX Yearly LT Debt VS Equity VS FCFNBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • NBTX has a Current Ratio of 0.63. This is a bad value and indicates that NBTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NBTX has a worse Current ratio (0.63) than 89.02% of its industry peers.
  • A Quick Ratio of 0.63 indicates that NBTX may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.63, NBTX is doing worse than 88.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
NBTX Yearly Current Assets VS Current LiabilitesNBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. NBTX Growth Analysis

3.1 Past

  • NBTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -47.30%.
  • NBTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -138.77%.
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%

3.2 Future

  • Based on estimates for the next years, NBTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.37% on average per year.
  • Based on estimates for the next years, NBTX will show a quite strong growth in Revenue. The Revenue will grow by 19.96% on average per year.
EPS Next Y78.75%
EPS Next 2Y21.41%
EPS Next 3Y22.51%
EPS Next 5Y13.37%
Revenue Next Year103.37%
Revenue Next 2Y50.74%
Revenue Next 3Y31.26%
Revenue Next 5Y19.96%

3.3 Evolution

NBTX Yearly Revenue VS EstimatesNBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M
NBTX Yearly EPS VS EstimatesNBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. NBTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NBTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBTX Price Earnings VS Forward Price EarningsNBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBTX Per share dataNBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • NBTX's earnings are expected to grow with 22.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.41%
EPS Next 3Y22.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NBTX Dividend Analysis

5.1 Amount

  • NBTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NBTX Fundamentals: All Metrics, Ratios and Statistics

NANOBIOTIX SA - ADR

NASDAQ:NBTX (3/23/2026, 4:30:01 PM)

30.54

+1.51 (+5.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)03-31
Inst Owners30.91%
Inst Owner Change0.82%
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap1.48B
Revenue(TTM)-14.04M
Net Income(TTM)-51.64M
Analysts85
Price Target27.27 (-10.71%)
Short Float %0.04%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.74%
PT rev (3m)18.14%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)60.53%
EPS NY rev (3m)42.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)63.81%
Revenue NY rev (3m)40.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS-0.34
BVpS-1.65
TBVpS-1.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.5%
Cap/Sales -3.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -11.18
F-Score2
WACC7.82%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-47.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y78.75%
EPS Next 2Y21.41%
EPS Next 3Y22.51%
EPS Next 5Y13.37%
Revenue 1Y (TTM)-138.77%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%186.77%
Revenue Next Year103.37%
Revenue Next 2Y50.74%
Revenue Next 3Y31.26%
Revenue Next 5Y19.96%
EBIT growth 1Y-159.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year89.69%
EBIT Next 3Y28.42%
EBIT Next 5Y0.48%
FCF growth 1Y14.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.92%
OCF growth 3YN/A
OCF growth 5YN/A

NANOBIOTIX SA - ADR / NBTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NANOBIOTIX SA - ADR (NBTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NBTX.


Can you provide the valuation status for NANOBIOTIX SA - ADR?

ChartMill assigns a valuation rating of 1 / 10 to NANOBIOTIX SA - ADR (NBTX). This can be considered as Overvalued.


Can you provide the profitability details for NANOBIOTIX SA - ADR?

NANOBIOTIX SA - ADR (NBTX) has a profitability rating of 0 / 10.